Amoxicillin/clavulanic acid controlled release - GlaxoSmithKline

Drug Profile

Amoxicillin/clavulanic acid controlled release - GlaxoSmithKline

Alternative Names: Amoxicillin 1000mg/clavulanic acid 62.5mg; Amoxicillin/clavulanic acid modified release; Augmentin SR; Augmentin XR; Extended-release amoxicillin/clavulanic acid; Pharmacokinetically enhanced amoxicillin/clavulanate - GSK

Latest Information Update: 22 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Beta-lactams; Penicillins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Acute sinusitis; Community-acquired pneumonia

Most Recent Events

  • 27 Jun 2005 Data presented at the 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2005) have been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 03 Nov 2003 Data presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA-2003) have been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 17 Oct 2003 Registered for Acute exacerbations of chronic bronchitis in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top